Botulinum Toxin Type A and Kinesitherapy of Post-stroke Patients
NCT ID: NCT00999180
Last Updated: 2011-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
40 participants
INTERVENTIONAL
2009-06-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis H(0): BT-A associated to kinesitherapy is not superior to kinesitherapy in the function of hemiparetic post-stroke patients.
H(1): BT-A associated to kinesitherapy is superior to kinesitherapy in the function of hemiparetic post-stroke patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Posteriorly the patients will be set in another room, where a neurologist will inject one of the two possible substances, with a pre-determined dosage and dilution. The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport) and the control group will have the syringe filled with saline. All the patients will be reassessed in three and six months for a new injection, and will undergo the last evaluation in nine months.
During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training (appendix D). There will be appointments twice a week, one day apart. The duration of the session will be 30 minutes, being 1 minute the interval between the activities. The first 5 minutes will comprise the flexibility exercises, with sustained stretching (15 seconds) and joint mobilizations, followed by a muscle strength exercise involving concentric and eccentric movements, with a progressive charge depending on the patient performance within the following 10 minutes. The last 15 minutes will have a functional training involving gait and upper limb activity combined with endurance training. These activities will be divided into two days: the first day for the trunk and upper limb, and the second for the pelvic, gait, and lower limb exercises. This protocol will be carried out by two physical therapist blinded regarding to the drug injection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Btx-A and Kinesiotherapy
The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
Botulinum toxin type A and kinesiotherapy
Stroke, Botulinum Toxin
Saline and Kinesiotherapy
The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
Saline and Kinesiotherapy
Saline and Kinesiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin type A and kinesiotherapy
Stroke, Botulinum Toxin
Saline and Kinesiotherapy
Saline and Kinesiotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients followed by the physical therapy staff at the IBR and HAS, with 2 appointments per week.
* Patients from both sexes with ages superior to 18 years
* To have the minimum of one a maximum of five years post post-stroke.
Exclusion Criteria
* Cognitive impairment
* Poorly controlled arterial hypertension
* Presence of joint blockade
* Unable to walk independently
* Use of orthesis as a gait aid
* Use of botulinum toxin within the last six months
* Use of systemic drugs for reduction of tonus
* Blood, liver, or kidney disorders and pregnant or lactating women
* Cardiopathy
* Comprehension aphasia
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal University of Bahia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ailton de Souza Melo
Botulinum Toxin Type A and Kinesitherapy Use in the Functional Performance of Post-stroke Patients
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ailton Melo, PHD
Role: PRINCIPAL_INVESTIGATOR
Federal University of Bahia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal University of Bahia
Salvador, Estado de Bahia, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UFBA-064
Identifier Type: -
Identifier Source: org_study_id